Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis

BackgroundThe relapsing-remitting dynamics is a hallmark of autoimmune diseases such as Multiple Sclerosis (MS). Although current understanding of both cellular and molecular mechanisms involved in the pathogenesis of autoimmune diseases is significant, how their activity generates this prototypical dynamics is not understood yet. In order to gain insight about the mechanisms that drive these relapsing-remitting dynamics, we developed a computational model using such biological knowledge. We hypothesized that the relapsing dynamics in autoimmunity can arise through the failure in the mechanisms controlling cross-regulation between regulatory and effector T cells with the interplay of stochastic events (e.g. failure in central tolerance, activation by pathogens) that are able to trigger the immune system.ResultsThe model represents five concepts: central tolerance (T-cell generation by the thymus), T-cell activation, T-cell memory, cross-regulation (negative feedback) between regulatory and effector T-cells and tissue damage. We enriched the model with reversible and irreversible tissue damage, which aims to provide a comprehensible link between autoimmune activity and clinical relapses and active lesions in the magnetic resonances studies in patients with Multiple Sclerosis. Our analysis shows that the weakness in this negative feedback between effector and regulatory T-cells, allows the immune system to generate the characteristic relapsing-remitting dynamics of autoimmune diseases, without the need of additional environmental triggers. The simulations show that the timing at which relapses appear is highly unpredictable. We also introduced targeted perturbations into the model that mimicked immunotherapies that modulate effector and regulatory populations. The effects of such therapies happened to be highly dependent on the timing and/or dose, and on the underlying dynamic of the immune system.ConclusionThe relapsing dynamic in MS derives from the emergent properties of the immune system operating in a pathological state, a fact that has implications for predicting disease course and developing new therapies for MS.

[1]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[2]  T. Braciale,et al.  Frequency, Specificity, and Sites of Expansion of CD8+ T Cells during Primary Pulmonary Influenza Virus Infection1 , 2005, The Journal of Immunology.

[3]  K. Herold,et al.  Type 1 diabetes as a relapsing–remitting disease? , 2007, Nature Reviews Immunology.

[4]  Jorge Carneiro,et al.  Inverse correlation between the incidences of autoimmune disease and infection predicted by a model of T cell mediated tolerance. , 2004, Journal of autoimmunity.

[5]  H. Kitano A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[6]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[7]  Anna Chodos,et al.  Antigen-dependent Proliferation of CD4+ CD25+ Regulatory T Cells In Vivo , 2003, The Journal of experimental medicine.

[8]  T. Vollmer,et al.  The natural history of relapses in multiple sclerosis , 2007, Journal of the Neurological Sciences.

[9]  Ethan M. Shevach,et al.  Suppressor Effector Function of CD4+CD25+ Immunoregulatory T Cells Is Antigen Nonspecific , 2000, The Journal of Immunology.

[10]  L. Steinman,et al.  Systems biology and its application to the understanding of neurological diseases , 2009, Annals of neurology.

[11]  S. Hauser,et al.  The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration , 2006, Neuron.

[12]  J Walker,et al.  Gene expression profiling in human peripheral blood mononuclear cells using high-density filter-based cDNA microarrays. , 2000, Journal of immunological methods.

[13]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[14]  John Doyle,et al.  Complexity and robustness , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Lawrence Steinman,et al.  Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.

[16]  Pablo Villoslada,et al.  Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates , 2001, European journal of immunology.

[17]  Susumu Tonegawa,et al.  High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice , 1994, Cell.

[18]  Shimon Sakaguchi,et al.  Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization , 2005, The Journal of experimental medicine.

[19]  W. Hop,et al.  Self reported stressful life events and exacerbations in multiple sclerosis:prospective study , 2003, BMJ : British Medical Journal.

[20]  C. van den Dool,et al.  When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells , 2007, Immunological reviews.

[21]  E. Nieuwenhuis,et al.  IPEX as a Result of Mutations in FOXP3 , 2007, Clinical & developmental immunology.

[22]  Stephen L Hauser,et al.  Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen , 1999, Journal of Neuroimmunology.

[23]  Stephen L. Hauser,et al.  The genetics of multiple sclerosis: SNPs to pathways to pathogenesis , 2008, Nature Reviews Genetics.

[24]  Nancy Richert,et al.  Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. , 2009, Archives of neurology.

[25]  Neal Jeffries,et al.  Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. , 2003, Brain : a journal of neurology.

[26]  W. Zhu,et al.  Stochastic analysis of a pulse-type prey-predator model. , 2008, Physical review. E, Statistical, nonlinear, and soft matter physics.

[27]  Robert M. May,et al.  Dynamical diseases , 1978, Nature.

[28]  Shimon Sakaguchi,et al.  IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. , 2004, International immunology.

[29]  Richard A Flavell,et al.  A protective function for interleukin 17A in T cell–mediated intestinal inflammation , 2009, Nature Immunology.

[30]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[31]  C Confavreux,et al.  Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.

[32]  Nadav M Shnerb,et al.  Angular velocity variations and stability of spatially explicit prey-predator systems. , 2006, Physical review. E, Statistical, nonlinear, and soft matter physics.

[33]  F. Powrie,et al.  Regulatory T cells in the control of immune pathology , 2001, Nature Immunology.

[34]  J. Sepulcre,et al.  A Network Analysis of the Human T-Cell Activation Gene Network Identifies Jagged1 as a Therapeutic Target for Autoimmune Diseases , 2007, PloS one.

[35]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[36]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[37]  C. Daub,et al.  BMC Systems Biology , 2007 .

[38]  A. Shaw,et al.  How T cells 'find' the right dendritic cell , 2008, Nature Immunology.

[39]  E. Shevach,et al.  Control of T‐cell activation by CD4+ CD25+ suppressor T cells , 2001, Immunological reviews.

[40]  L. Klein,et al.  A central role for central tolerance. , 2006, Annual review of immunology.

[41]  Ronald N. Germain,et al.  The Art of the Probable: System Control in the Adaptive Immune System , 2001, Science.

[42]  Robert B Darnell,et al.  Autoimmune encephalopathy: The spectrum widens , 2009, Annals of neurology.

[43]  E. Sercarz,et al.  T cell vaccination in experimental autoimmune encephalomyelitis: a mathematical model. , 1998, Journal of immunology.

[44]  D. McFarlin,et al.  Immunological aspects of demyelinating diseases. , 1992, Annual review of immunology.

[45]  Erwin Frey,et al.  Coexistence versus extinction in the stochastic cyclic Lotka-Volterra model. , 2006, Physical review. E, Statistical, nonlinear, and soft matter physics.

[46]  J. Frank,et al.  The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis , 1995, Annals of neurology.

[47]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[48]  Antonio A. Freitas,et al.  Indexation as a Novel Mechanism of Lymphocyte Homeostasis: The Number of CD4+CD25+ Regulatory T Cells Is Indexed to the Number of IL-2-Producing Cells1 , 2006, The Journal of Immunology.

[49]  D. Paty,et al.  Early onset multiple sclerosis: A longitudinal study , 2002, Neurology.

[50]  Heli Tuovinen,et al.  A Defect of Regulatory T Cells in Patients with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy1 , 2007, The Journal of Immunology.

[51]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Borghans,et al.  A minimal model for T-cell vaccination , 1995, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[53]  C. Goodnow,et al.  Cellular and genetic mechanisms of self tolerance and autoimmunity , 2005, Nature.

[54]  Yasmine Belkaid,et al.  Natural regulatory T cells in infectious disease , 2005, Nature Immunology.

[55]  W. Hop,et al.  Prospective study on the relationship between infections and multiple sclerosis exacerbations. , 2002, Brain : a journal of neurology.

[56]  N. Burroughs,et al.  Regulatory T cell adjustment of quorum growth thresholds and the control of local immune responses. , 2006, Journal of theoretical biology.

[57]  Stephen T. C. Wong,et al.  Coordination of Early Protective Immunity to Viral Infection by Regulatory T Cells , 2022 .

[58]  E V Albano,et al.  Critical and oscillatory behavior of a system of smart preys and predators. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.

[59]  Hans D. Ochs,et al.  IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity , 2007, Immunologic research.

[60]  K. Wucherpfennig,et al.  Mechanisms for the induction of autoimmunity by infectious agents. , 2001, The Journal of clinical investigation.

[61]  Svetlana Ten,et al.  Multiple immuno-regulatory defects in type-1 diabetes. , 2002, The Journal of clinical investigation.

[62]  Pablo Villoslada,et al.  IL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis , 2008, European journal of immunology.

[63]  A. Rudensky,et al.  A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3 , 2005, Nature Immunology.